Merit Medical Systems has delivered a 34.9% share price gain over the past three years, which naturally puts the focus on one question for investors. Is the current US$87.21 price properly supported by the cash flows the business is expected to generate?
-
The 34.9% return over three years means anyone looking at Merit Medical Systems today is really asking whether that past share performance lines up with the value of the cash it can produce over time.
-
The group relies on recurring demand for its medical devices, so the way it converts that revenue into steady free cash flow and how much reinvestment it needs may heavily influence what counts as a reasonable valuation.
-
Prefer to judge Merit Medical Systems on earnings? See why Merit Medical Systems's 35.8x P/E tells a different valuation story .
The issue now is whether those projected cash flows point to an intrinsic value that can justify where Merit Medical Systems trades today.
If you are evaluating Merit Medical Systems in terms of its cash flows, it may be useful to compare those cash flows with a broader range of companies using the 28 high quality undervalued stocks
Is Merit Medical Systems a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) approach here looks at what Merit Medical Systems could return to shareholders through future free cash flows, expressed in today's dollars. On the cash side, the business produced about $219.4 million in free cash flow over the last twelve months, and analysts expect that figure to rise into the mid $200 million range within the next few years based on the projections used in this model.
Those estimates build in a pattern of growing but fairly measured free cash flows rather than a boom and bust profile, which fits a company tied to recurring medical device demand. When those cash streams are discounted back and compared with the current share price of $87.21, the DCF output suggests Merit Medical Systems' estimated intrinsic value is meaningfully above where the stock trades right now. Find out what Merit Medical Systems could be worth using our Discounted Cash Flow (DCF) estimate .
The Merit Medical Systems Narrative: What Would Justify Today's Price?
Narratives pick up where the DCF puzzle leaves off for Merit Medical Systems by spelling out which paths for growth, profitability and earnings would need to play out for the shares to be worth materially more or less than today's price, and they sit on Simply Wall St's Community page.
Each Narrative treats Merit Medical Systems' valuation as a thesis about how the business could develop over time, so you can see how that story holds up as fresh information arrives.
Community views on Merit Medical Systems are split between a margin-focused upside story and a more cautious take on execution and tariffs.
Bull case: 14% undervalued
"Merit Medical Systems is still working through multi year efficiency programs that have already lifted non GAAP operating margin to 22.6% in Q2 2026..."
Discover why this Narrative puts Merit Medical Systems at 14% undervalued .
Bear case: 5% overvalued
"Execution risk around acquisitions and platform expansion is rising, as the View Point Medical deal is initially dilutive to 2026 non GAAP EPS by about US$0.05..."
Explore why this Narrative puts Merit Medical Systems at 5% overvalued .
One more piece of the Merit Medical Systems puzzle to check
Before you lean too hard on any valuation result for Merit Medical Systems, it is worth knowing that Simply Wall St's broader checks have flagged specific areas of concern that could change how you view the risk profile. Take a closer look at 1 warning sign before settling on a valuation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MMSI .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
